Compare
Treace Medical Concepts, Inc. vs SI-BONE, Inc. vs Orthopediatrics Corp vs Neuronetics, Inc.
| Latest fiscal year | Treace Medical Concepts, Inc. TMCI | SI-BONE, Inc. SIBN | Orthopediatrics Corp KIDS | Neuronetics, Inc. STIM |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $212.69M | $200.93M | $236.35M | $149.16M |
| Revenue growth (YoY) | +1.6% | +20.2% | +15.4% | +99.2% |
| Gross margin | 79.8% | 79.6% | 73.1% | 48.5% |
| Operating margin | -25.5% | -11.1% | -16.6% | -21.1% |
| Net margin | -27.7% | -9.4% | -16.8% | -26.1% |
| Net income | -$59.00M | -$18.90M | -$39.65M | -$39.00M |
| EPS (Diluted) | -$0.93 | -$0.44 | -$1.69 | -$0.59 |
| Operating cash flow | -$15.97M | -$675.0K | -$4.85M | -$20.37M |
| Free cash flow | -$29.49M | -$9.09M | -$15.96M | -$21.18M |
| Cash & equivalents | $10.71M | $42.24M | $19.56M | $28.13M |
| Total assets | $190.58M | $238.56M | $508.63M | $141.55M |
| Total liabilities | $103.25M | $61.02M | $162.03M | $115.31M |
| Shareholders' equity | $87.33M | $177.53M | $346.60M | $22.38M |
| Return on year-end equity | -67.6% | -10.6% | -11.4% | -174.3% |
| Shares outstanding | n/a | 43.65M | 25.09M | 68.99M |
Revenue, most recent five fiscal years
| Fiscal year | Treace Medical Concepts, Inc. | SI-BONE, Inc. | Orthopediatrics Corp | Neuronetics, Inc. |
|---|---|---|---|---|
| Latest | $212.69M Ended 2025-12-31 | $200.93M Ended 2025-12-31 | $236.35M Ended 2025-12-31 | $149.16M Ended 2025-12-31 |
| 1 year earlier | $209.36M Ended 2024-12-31 | $167.18M Ended 2024-12-31 | $204.73M Ended 2024-12-31 | $74.89M Ended 2024-12-31 |
| 2 years earlier | $187.12M Ended 2023-12-31 | $138.89M Ended 2023-12-31 | $148.73M Ended 2023-12-31 | $71.35M Ended 2023-12-31 |
| 3 years earlier | $141.84M Ended 2022-12-31 | $106.41M Ended 2022-12-31 | $122.29M Ended 2022-12-31 | $65.21M Ended 2022-12-31 |
| 4 years earlier | $94.42M Ended 2021-12-31 | $90.15M Ended 2021-12-31 | $98.05M Ended 2021-12-31 | $55.31M Ended 2021-12-31 |